← Back to Search

Active tDCS for Depression

Phase 2 & 3
Waitlist Available
Led By Marcelo T. Berlim, MD, MSc
Research Sponsored by Douglas Mental Health University Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Presence of a current major depressive disorder (according to the Diagnostic and Statistical Manual, Fourth Edition, Text Revision [DSM-IV-TR])
Baseline score ≥ 13 on the QIDS-C
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

Study Summary

Transcranial direct current stimulation (tDCS) is a noninvasive method to activate or de-activate neurons in superficial regions of the brain through the induction of weak electric currents in the brain tissue delivered by two scalp electrodes. Initial studies have shown tDCS to be effective for treating major depressive disorder (MDD), although there are negative trials in the specialized literature. One reason for these discrepant results might be that the duration of tDCS treatment in clinical trials to date (up to 2 weeks) is still insufficient to produce consistent clinical improvements. Thus, we intend to assess, in a sample of outpatients with MDD, whether a 3-week adjunctive course of active tDCS over the left dorsolateral prefrontal cortex is associated with a significant clinical improvement when compared to sham tDCS. The investigators hypothesize that subjects receiving active tDCS will present with significantly higher response and remission rates at weeks 3.

Eligible Conditions
  • Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C)
Secondary outcome measures
21-item Hamilton Depression Rating Scale (HAM-D21)
Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
Car accident
2%
skin irritation
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active tDCSExperimental Treatment1 Intervention
Group II: Sham tDCSPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Douglas Mental Health University InstituteLead Sponsor
29 Previous Clinical Trials
2,696 Total Patients Enrolled
7 Trials studying Depression
276 Patients Enrolled for Depression
Marcelo T. Berlim, MD, MScPrincipal InvestigatorMcGill University & Douglas Mental Health University Institute
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Depression
10 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025